Thanks trding. This may have been stated elsewhere, but it's interesting that their model doesn't include oncology at all. I understand why (too remote/contingent/difficult to value), but it underscores how potentially undervalued CYDY is that someone puts a $1.50 target on CYDY without considering any indication but HIV.